Enerji Metabolizması Enzimlerinden İzositrat Dehidrogenazla İlgili Çalışmaların Bibliyometrik Analizi

Yıl 2023, Cilt: 13 Sayı: 2, 437 - 444, 30.05.2023

Cem Yalaza

https://doi.org/10.31020/mutftd.1262989

Cited By: 1

Öz

Amaç: İzositrat dehidrogenaz (IDH), krebs döngüsünde ve hücresel enerji metabolizmasında yer alan önemli bir enzimdir. Birçok kanser türünde prognostik, diyagnostik ve terapötik bir hedef olduğu belirtilmektedir. Bu durum IDH enzimini popüler bir çalışma konusu haline getirmektedir. Bu çalışmada da, IDH molekülünün bibliyometrik göstergeler kullanılarak WoS veri tabanında incelenmesi, yapılan çalışmaların Türkiye ölçeğinde değerlendirilmesi ve geleneksel tıbbın bu çalışmalardaki yerinin belirlenmesi amaçlanmıştır.
Yöntem: WoS veri tabanında “IDH”, “Isocitrate dehydrogenase” ve “traditional medicine” anahtar kelimeleri ile tarama yapılmıştır. Bu taramada özet, başlık ve anahtar kelimelerde arama gerçekleştirilmiş, 1980-2022 yılları arasında yayınlanmış orijinal araştırma makalelerinin verilerine erişebilmek için “Article” seçeneği kullanılmıştır.
Bulgular: Konuyla ilgili 11.982 yayın içerisinde 2022 yılının sonuna kadar toplamda 9.103 araştırma makalesine ulaşılmıştır. Son yıllarda çalışma sayılarında artış olduğu, en fazla sayıda makalenin 2021 yılında yayınlandığı (n=995), en çok kullanılan dilin %98,363 ile İngilizce olduğu, en üretken ülkenin 2.696 çalışmayla ABD olduğu, Türkiye’nin 97 çalışmayla 23. sırada yer aldığı tespit edilmiştir. Geleneksel tıpla ilgili 16 araştırma makalesinin yayınlandığı belirlenmiştir.
Sonuç: IDH günümüzde güncel bir çalışma konusudur. Buna rağmen, geleneksel tıpla ilgili çalışmalar ise çok az sayıdadır. Türkiye adresli çalışmaların bu güncel konuyla ilgili uluslararası sıralamalardaki yerini daha yukarılara taşıyabilmesi için daha çok çalışmanın yapılması ve makalenin yayınlanması gerekmektedir.

Anahtar Kelimeler

IDH, WoS, Bibliyometri, Geleneksel Tıp

Destekleyen Kurum

-

Proje Numarası

-

Bibliometric Analysis of Studies on the Energy Metabolism Enzyme Isocitrate Dehydrogenase

Öz

Objective: Isocitrate dehydrogenase (IDH) is an important enzyme involved in the Krebs cycle and cellular energy metabolism. It is stated to be a prognostic, diagnostic, and therapeutic target in many cancer types. This makes the IDH enzyme a popular subject of scientific research. This current study aimed to examine the IDH molecule in the WoS database using bibliometric indicators, evaluate the studies conducted in Turkey, and determine the place of traditional medicine in IDH studies.
Materials and Methods: "IDH", "Isocitrate dehydrogenase", and “traditional medicine” keywords were used for search in the WoS database. This search was performed in the abstract, title, and keywords. The "Article" option was used to access the data of original research articles published between 1980-2022.
Results: A total of 9.103 research articles were reached by the end of 2022 among 11.982 publications. It has been determined that there has been an increase in the number of studies in recent years, the highest number of articles were published in 2021 (n=995), the most used language was English with 98,363%, the most productive country was the USA with 2.696 studies, and Turkey ranked 23rd with 97 studies. It has been determined that 16 research articles about traditional medicine have been published.
Conclusion: IDH is a current research topic. However, studies on traditional medicine about IDH are very few. More research should be done and more articles should be published for the studies from Turkey to take place in the international rankings on this current topic.

Anahtar Kelimeler

IDH, WoS, Bibliometry, Traditional Medicine

Proje Numarası

-

Kaynakça

• 1. Fujii T, et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med 2016;21(117):373-80.
• 2. Al-Khallaf H. Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. Cell & Bioscience 2017;7:37.
• 3. Mardis ER, et al. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. The New England Journal of Medicine 2009;361(11):1058–1066.
• 4. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Annals of Oncology 2016;27(4):599-608.
• 5. Tommasini-Ghelfi S, et al. Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Sci Adv 2019;22;5(5):eaaw4543.
• 6. Yalaza C, et al. Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis. Arch Gynecol Obstet 2020;302(5):1221-1227.
• 7. Bunevicius A, Miller J, Parsons M. Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review. Curr Oncol Rep 2020;22:120.
• 8. Minemura H, et al. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen‑receptor positive cases. Breast Cancer 2021;28:915–926.
• 9. Raja Ikram RR, Abd Ghani MK, Abdullah N. An analysis of application of health informatics in Traditional Medicine: A review of four Traditional Medicine Systems. Int J Med Inform 2015;84(11):988-996.
• 10. Bai H, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet 2016;48(1):59-66.
• 11. Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;26;321(5897):1807-12.
• 12. Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;19;360(8):765-73.
• 13. Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;10;462(7274):739-44.
• 14. Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;14;18(6):553-67.
• 15. Brat DJ, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015;25;372(26):2481-98.
• 16. Ward PS, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;16;17(3):225-34.
• 17. Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;15;483(7390):474-8.
• 18. Turcan S, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;15;483(7390):479-83.
• 19. Eckel-Passow JE, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 2015;25;372(26):2499-508.
• 20. Metallo CM, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2011;20;481(7381):380-4.
• 21. Han J, et al. Mapping the intellectual structure of research on surgery with mixed reality: Bibliometric network analysis (2000-2019). J Biomed Inform 2020;109:103516.
• 22. Donthu N, et al. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res 2021;133, pp. 285-296.
• 23. Abdullah KG, Adamson C, Brem S. The Molecular Pathogenesis of Glioblastoma. Elsevier 2016;Pages 21-31.
• 24. He Q, et al. Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance. Cancers 2022;14(23):5779.
• 25. Jiang S, Zanazzi GJ, Hassanpour S. Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images. Sci Rep 2021;11:16849.